Mannose-Binding Lectin as a Predictor of Microalbuminuria in Type 1 Diabetes
An Inception Cohort Study
- Peter Hovind1,
- Troels Krarup Hansen2,
- Lise Tarnow1,
- Steffen Thiel3,
- Rudi Steffensen4,
- Allan Flyvbjerg2 and
- Hans-Henrik Parving15
- 1Steno Diabetes Center, Gentofte, Denmark
- 2Medical Department M (Immunoendocrine Research Unit) and Medical Research Laboratories, Aarhus University Hospital, Aarhus, Denmark
- 3Department of Medical Microbiology and Immunology, University of Aarhus, Aarhus, Denmark
- 4Department of Clinical Immunology, Aalborg Hospital, Aalborg, Denmark
- 5Faculty of Health Science, University of Aarhus, Aarhus, Denmark
- Address correspondencereprint requests to Peter Hovind, MD, Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark. E-mail: phovind{at}dadlnet.dk
Abstract
Inflammation and complement activation via the mannose-binding lectin (MBL) pathway have been suggested to play a role in the pathogenesis of diabetic microvascular complications. The association between the complement-activating protein MBL and the development of persistent microalbuminuria was evaluated in an inception cohort of 286 newly diagnosed type 1 diabetic patients consecutively admitted to the Steno Diabetes Center between 1 September 1979 and 31 August 1984. Serum MBL was measured with an immunofluorometric assay in 270 of the patients (159 men) after 3 years of diabetes duration. During the median (range) follow-up period of 18.0 (1.0–21.8) years, 75 patients subsequently progressed to persistent micro- or macroalbuminuria (urinary albumin excretion rate >30 mg/24 h). In patients with MBL levels above the median (1,597 μg/l), the cumulative incidence of persistent micro- or macroalbuminuria was 41% (CI 31–50) as compared with 26% (CI 17–34) in patients with MBL levels below the median (log-rank test, P = 0.003). In a Cox proportional hazard model with sex and age as fixed covariates, MBL was independently associated with later development of persistent micro- or macroalbuminuria (hazard ratio 1.21 [CI 1.02–1.42] per 1,000 μg/l increase in MBL; P = 0.03) after adjusting for possible confounders. In our study, high levels of MBL early in the course of type 1 diabetes was significantly associated with later development of persistent micro- or macroalbuminuria, suggesting that complement activation initiated by MBL may be involved in the pathogenesis of diabetic microvascular complications.
Footnotes
-
- Accepted February 7, 2005.
- Received December 16, 2004.
- DIABETES











